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The decision to administer systemic therapy should 
be made by a multidisciplinary team consisting of 
oncologists, radiotherapists, surgeons, nurses and 
social workers.
For breast cancer it is given for three reasons:
• neoadjuvant therapy to reduce tumour bulk before definitive 
surgery
• adjuvant therapy after surgery to control micrometastatic disease, 
and 
• to reduce tumour bulk and improve quality of life in metastatic 
disease.
Any adjuvant agent can be given in metastatic therapy, but the aim 
of treatment here is to reduce tumour-related side-effects. As it is not 
the objective to replace the latter by treatment-related side-effects, 
metastatic disease is treated with single-agent sequential drugs, while 
adjuvant therapy employs drug combinations aimed at eliminating 
micrometastatic disease and reducing drug resistance.
The downside of combination therapy is an increase in side-effects. 
There are many new drugs being used for cancer management 
and the alleviation of side-effects. One of the major advances in 
the management of nausea associated with chemotherapy is the 
improvement in anti-emetic medication.
Systemic therapy is divided into: 
• endocrine therapy
• chemotherapy, and
• biological response modifier therapy.
Before embarking on any systemic therapy, patients should be 
counselled, as all therapies will cause a higher rate of anxiety and 
depression, and loss of libido, which for many is a major problem.
In pre-menopausal patients fertility issues should be discussed, as 
systemic therapies can cause a decrease in or, in some cases, loss of 
fertility. 
Endocrine therapy
Endocrine therapy is designed to reduce oestrogen availability to 
oestrogen receptor (ER)-positive tumour cells and to reduce tumour 
growth. In the pre-menopausal patient this is done by blocking the 
cellular surface oestrogen receptor by using a hormone receptor 
antagonist, e.g. tamoxifen, or by eliminating oestrogen production 
by blocking functioning ovaries with a luteinising hormone-releasing 
hormone (LHRH) analogue (effectively a chemical oophorectomy). 
In post-menopausal patients endocrine therapy blocks the production 
of oestrogen from androgens under the influence of the aromatase 
enzyme complex by using aromatase inhibitors.
The generalised effects of these drugs are to reduce oestrogen 
availability; therefore side-effects such as hot flushes, genito-urinary system 
dysfunction, e.g. vaginal dryness, bladder irritability, and loss of libido are 
common in both pre-menopausal and post-menopausal patients.
Pre-menopausal women
Tamoxifen is the most common endocrine chemotherapeutic agent 
used. Its major side-effects are hot flushes, weight gain, loss of 
libido and sexual dysfunction, mood swings, some vaginal dryness 
and bladder irritability, altered menstrual cycles and ovarian cysts. 
Patients should be warned not to become pregnant while on 
tamoxifen as it is teratogenic. An increased incidence of deep vein 
thrombosis and pulmonary embolus has been reported, along with 
ocular toxicity, mainly retinopathy, macular oedema and cataracts. 
LHRH analogues are used in patients who cannot tolerate 
tamoxifen. This places the patient into menopause, with hot flushes, 
amenorrhoea, and associated menopausal side-effects. Bone mineral 
density (BMD) is also reduced and should be monitored.
Post-menopausal women
Aromatase inhibitors
As aromatase inhibitors deprive post-menopausal women of 
oestrogen, menopausal effects are exaggerated, The main side-effects 
are hot flushes, arthralgias and myalgias, reduced libido, a dry vagina 
and skin, and thinning of hair. As BMD is reduced, it should be 
carefully monitored (the main reduction is in the first two years of 
therapy). If necessary, a bisphosphonate can be given in combination 
with the aromatase inhibitor.
Tamoxifen 
This drug is also administered to post-menopausal patients, with 
the same side-effects as in pre-menopausal women, except for the 
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menstrual changes. However, tamoxifen has a weak oestrogenic 
effect on the endometrium without the protection of endogenous 
progesterone production in pre-menopausal patients. Consequently, 
there have been reported cases of endometrial carcinoma because of 
the unopposed oestrogen stimulation with this agent. The incidence 
is small and the tumours are mainly low grade, but regular follow-up 
by a gynaecologist is recommended.
Selective oestrogen receptor modulators (SERMs) 
SERMs modify the ER and prevent downstream signalling. As these 
agents are given by intramuscular injection, one of the side-effects is pain 
at the injection site. Other side-effects are hot flushes and weight gain.
Chemotherapy
Neoadjuvant and adjuvant chemotherapy are given using multiple 
drug regimens to achieve maximum efficacy, but this leads to an 
increase in side-effects. All side-effects are increased in patients >60 
years and in those with comorbid medical conditions, e.g. diabetes, 
hypertension, infections, or recent surgery.
Common combinations used in breast cancer are those containing 
an anthracycline such as adriamycin (A) or 4’epi-adriamycin (E) with 
cyclophosphamide (C), 5-fluorouracil (5-FU) (F) and a taxane (T) such 
as docetaxel or paclitaxel. Commonly used regimens are FEC plus T, 
AC plus T, CAF and CEF. Less commonly, the older regimen of CMF 
(cyclophosphamide, methotrexate and 5-FU) is used.
Common side-effects 
Myelosuppression is often a dose-limiting toxicity, with leucopenia 
being more common than thrombocytopenia or anaemia. Scheduling 
of the regimen is based on the nadir of myelosuppression. 
Nausea and vomiting, once severe with many regimens, is now well 
controlled with new intravenous and oral anti-emetics, and is rarely 
problematic. Complete alopecia often occurs with many regimens, 
but is nearly always reversible within 3 - 6 months after completion 
of chemotherapy. Tiredness is common and not fully understood, as 
it is often unrelated to anaemia or anorexia. 
Neurotoxicity can occur with the class of drugs known as spindle 
blockers and is a dose-dependent effect. The most commonly used 
agents in breast cancer are paclitaxel and docetaxel. Peripheral 
neuropathy is the most common side-effect with numbness and 
paraesthesia of the fingers and toes. Neurotoxicity is less commonly 
seen with vinorelbine.
Many of the chemotherapies used can lead to hypersensitivity 
reactions – from mild skin rashes to hypotension, dyspnoea, and 
bronchospasm.
Mucositis, oral ulcers, dry itchy eyes and bladder sensitivity with 
chemical cystitis may occur with varying frequency. Most of the 
drugs used have some or all of these side-effects, which are very rarely 
problematic.
Plantar palmar erythema is more commonly seen with drugs 
used in metastatic disease, such as oral 5-FU combinations, e.g. 
capecitabine or liposomal doxorubicin, when the palms and soles 
become red and very sensitive, sometimes blistering.
Because many of the drugs given intravenously are potent vesicants, 
one must ensure that there is absolutely no extravasation of any drug. 
Even so, anthracyclines in particular can cause pain and phlebitis at a 
site of venous drainage away from the needle insertion.
Cardiotoxicity 
The main drugs responsible for cardiotoxicity are the anthracyclines. 
The changes may be acute and transitory, but may occur late and 
cause severe cardiac damage. Myocytes of the cardiac muscle are 
damaged permanently and the long-term effects are dependent on 
the extent of the damage. As patients survive longer after adjuvant 
therapy, they present with late cardiac problems. These changes are 
less when the doses are based on body surface area (m2) calculations, 
but can occur idiosyncratically with small doses. Cardiologists 
stress the need for careful cardiac monitoring. Even in the case of a 
normal echocardiogram, if the ejection fraction has decreased by as 
little as 10%, the patient should be referred to a cardiologist. Other 
drugs such as cyclophosphamide, 5-FU and paclitaxel can also cause 
cardiotoxicity, but less commonly in the doses used.
All side-effects, except for alopecia, are manageable and reduced or 
eliminated by premedication and dose scheduling according to body 
surface area. It is important to discuss all side-effects with the patient 
before treatment so that they are fully informed.
Biological response modifiers 
Monoclonal antibodies
Trastuzumab
Trastuzumab is the best-known example of this class of drug, which 
blocks HER2 receptors, down-regulating the HER2 expression and 
interrupting cell signalling pathways. The main toxicities are infusion-
related with chills, headache, generalised pains and occasionally 
hypersensitivity. Care must be taken when treating patients with pre-
existing cardiac dysfunction, as a decrease in left ventricular ejection 
fraction (LVEF) and congestive cardiac failure can occur.
Bevacizumab
This drug inhibits malignant angiogenesis. Toxicities include 
bleeding complications and thromboembolic events, including 
myocardial infarction, stroke and angina. Hypertension, proteinuria 
and nephrotic syndrome can occur. Hypersensitivity may manifest as 
fever and chills. Common central nervous system symptoms include 
dizziness and depression.
Small molecules
Lapatinib
This is a tyrosine kinase inhibitor that blocks intracellular downstream 
signalling. Side-effects include skin rash, myelosuppression, 
neurotoxicity, fatigue, nausea, vomiting, diarrhoea and myalgia and 
arthralgia.
Everolimus
This is an m-TOR inhibitor that blocks intracellular signalling 
pathways. Side-effects may include fatigue, oral ulcers, nausea, 
vomiting, opportunistic infections and pulmonary toxicity. 
Hyperlipidaemia and hyperglycaemia may also occur.
Conclusion
The management of breast cancer has become more personalised 
and a multidisciplinary team should decide on the systemic regimens 
used. In future, more targeted therapies will be used. Most side-
effects resulting from chemotherapy can be managed. The newer 
drugs are not less toxic than the older ones, but their side-effects must 
be managed differently.
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